Systemic sclerosis & Raynaud's
Autologous stem cell transplantation improves cardiopulmonary exercise testing outcomes in systemic sclerosis patients
Authors' conclusion
AHSCT improves the aerobic capacity of SSc patients probably reflecting combined increments in lungs, skeletal muscle and cardiac function.
Study context
- Population
- Adults with severe SSc treated with autologous haematopoietic stem cell transplantation (AHSCT); most dcSSc (93%) and pulmonary involvement (85%)
- Participants
- 27 adults
- Exposure
- Before vs 12 months after autologous haematopoietic stem cell transplantation
- Outcome
- Cardiopulmonary function outcomes (cardiopulmonary exercise testing)
- Follow-up
- 12 months
Methodological detailsbefore-and-after (baseline and 12 months after AHSCT)
- Before-and-after (baseline and 12 months after AHSCT)
Main finding
As reported in the abstract
Peak VO2
P = 0.02
Observational data: associations, not effects.
Further findings
Percentage of predicted peak VO2 · 12 months
P = 0.01
6MWT distance · 12 months
P = 0.01
- Peak VO2 by baseline DLCO (>70% vs <70%) · higher peak VO2 at baseline with DLCO >70%
- P = 0.04
Correlations of peak VO2 improvement
- Improvements in peak VO2 correlated positively with improvements in 6MWT distance, and negatively with a decrease in resting heart rate
Peak VO2 by baseline DLCO (>70% vs <70%)
- After AHSCT all patients showed improved VO2 values, regardless of baseline DLCO levels
Correlation of VO2 increase with SF-36 physical component score increase
- R
- 0.70
- P
- P = 0.0003
Original publication
Autologous stem cell transplantation improves cardiopulmonary exercise testing outcomes in systemic sclerosis patients. Rheumatology (Oxford). Published 21 July 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →